total hip replacement
Conditions
Interventions
Picysular nerve block (Group P)
:0.3% ropivacaine 30mL. Picysular nerve block
Iliafascial space block in supra-inguinal approach (Group F):0.3% ropivacaine 30mL. Iliafascial space block in supra-inguinal approach
Sponsors
The First Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age: >= 18 years old; 2. ASA grade I-III; 3. Patients undergoing primary total hip replacement under composite nerve block under general anesthesia
Exclusion criteria
Exclusion criteria: 1. Allergy or intolerance to any drug used in the study ; 2. With other serious systemic diseases (serious heart, kidney, or liver lung disease): Goldman score 13; patients with renal insufficiency (blood creatinine, urea nitrogen is 1.2 times the normal range) or abnormal liver function AST / ALT is 1 / 5 / 2 times the normal; maximum vital capacity (FVC) 30 kg/m^2 ;; 5 Patients who are expected to transfer to the ICU after surgery 6. Coagulation dysfunction 7 existing neurological or anatomical defects in the lower limbs 8. Infection at the block site
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain scores at 24h postoperative exercise (passive straight leg elevation 15) were assessed using the NRS Digital Pain Assessment Scale; | — |
Countries
China
Contacts
Public ContactSun Defeng
The First Affiliated Hospital of Dalian Medical University
Outcome results
None listed